Article Information
vol. 11 no. 505
- Received for publication January 6, 2019
- Accepted for publication July 1, 2019
- .
Author Information
- E. Antonio Chiocca1,2,*,
- John S. Yu3,
- Rimas V. Lukas4,5,6,
- Isaac H. Solomon7,
- Keith L. Ligon7,
- Hiroshi Nakashima1,
- Daniel A. Triggs1,
- David A. Reardon2,
- Patrick Wen2,
- Brittany M. Stopa1,
- Ajay Naik1,
- Jeremy Rudnick3,
- Jethro L. Hu3,
- Priya Kumthekar4,5,
- Bakhtiar Yamini6,
- Jill Y. Buck8,
- Nathan Demars8,
- John A. Barrett8,
- Arnold B. Gelb8,
- John Zhou8,
- Francois Lebel8 and
- Laurence J. N. Cooper8,9
- 1Department of Neurosurgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA.
- 2Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
- 3Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
- 4Ken and Ruth Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
- 5Lou and Jean Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA.
- 6University of Chicago, Chicago, IL 60637, USA.
- 7Division of Neuropathology, Department of Pathology, Brigham and Women’s Hospital, Boston, MA 02115, USA.
- 8Ziopharm Oncology, Inc., One First Avenue, Parris Building 34, Navy Yard Plaza, Charlestown, Boston, MA 02129, USA.
- 9MD Anderson Cancer Center, University of Texas, Houston, TX 77030, USA.
- ↵*Corresponding author. Email: eachiocca{at}bwh.harvard.edu